

ASX release

29 August 2017

## Share Purchase Plan

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, is pleased to announce that, following on from the recent \$825,000 share placement, the company is now offering a Share Purchase Plan (SPP) to raise up to a further \$500,000.

Directors have advised they will participate in the offer, contributing at least \$80,000. A further \$270,000 will be underwritten by the company's brokers. The SPP will allow existing eligible shareholders to subscribe for up to \$15,000 of new AtCor shares. The price has been set at \$0.027 per share, representing a 18% discount to the 5 day volume weighted average price.

The funds will be used to provide additional working capital to support the key initiatives outlined in the company's strategic review update announced on 2 August 2017. These include an increased focus on advancing strategic options and securing new sales; restructuring operations to maximise profitability; and working to realise new revenue streams for SphygmoCor® technology, in both the high-end consumer and prescription based markets.

Under the SPP rules, shareholders recorded on the register at 28 August 2017 (record date) with a registered address in Australia or New Zealand will be eligible to participate. Each eligible shareholder will be entitled to apply for up to \$15,000 of new fully paid ordinary shares of the Company without incurring any brokerage or other transaction costs. All new shares issued under the SPP will rank equally with existing ordinary shares of the Company.

The closing date for participation in the SPP will be Monday, 18 September 2017.

Application forms and formal offer documents will be mailed to eligible shareholders on 5 September 2017.

### About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor® is essential for hypertension diagnosis and management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact (AtCor):*

Duncan Ross . AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley . AtCor Medical CFO  
+61 (2) 8815 8811

*Media enquiries to:*

Ashley Rambukwella . Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282  
or [a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)